The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PHIO | -52.18% | -99.49% | -65.2% | -100% |
| S&P | +14.18% | +88.25% | +13.47% | +404% |
Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.00M | 0.0% |
| Market Cap | $14.20M | 378.3% |
| Market Cap / Employee | $2.84M | 0.0% |
| Employees | 5 | -44.4% |
| Net Income | -$2.39M | -57.0% |
| EBITDA | -$2.50M | -57.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $10.71M | 98.6% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -91.57% | 4.8% |
| Return On Invested Capital | -104.41% | -1.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.09M | -7.1% |
| Operating Free Cash Flow | -$2.09M | -6.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.35 | 0.48 | 0.92 | 1.18 | 152.67% |
| Price to Tangible Book Value | 0.35 | 0.48 | 0.92 | 1.18 | 152.67% |
| Enterprise Value to EBITDA | 1.35 | 4.10 | -0.21 | -1.14 | -191.92% |
| Return on Equity | -114.8% | -76.1% | -102.2% | -107.6% | -11.84% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
